Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu

Open access
Cooley, Sarah, Burns, Linda J, Repka, Tanya, Miller, Jeffrey S · 1999 · Experimental Hematology

Abstract

Treatment of advanced breast cancer with autologous stem cell transplantation is limited by a high probability of disease relapse. In clinical trials, interleukin 2 (IL-2) alone can expand natural killer (NK) cells in vivo and increase their cytotoxic activity against breast cancer cell lines, but this increase is modest. Understanding the mechanisms that mediate NK cell lysis of breast cancer targets may lead to improvements of current immunotherapy strategies. NK cells from normal donors or patients receiving subcutaneous IL-2 were tested in cytotoxicity assays against five breast cancer cell lines. The role of adhesion molecules and antibodies that interact through Fc receptors on NK cells was explored. NK cell lysis of breast cancer targets is variable and is partially dependent on recognition through ICAM-1 and CD18. While blocking CD2 slightly decreased cytotoxicity, contrary to expectations, an antibody against CD58 (the ligand for CD2), failed to block killing and instead mediated an increased cytotoxicity that correlated with target density of CD58. The CD58 antibody-enhanced killing was dependent not only on FcRgammaIII but also on CD2 and ICAM-1/CD18. To further elucidate the mechanism of this CD58 antibody-dependent cellular cytotoxicity (ADCC), another antibody was tested. Trastuzumab (Herceptin), a humanized antibody against HER2/neu, mediated potent ADCC against all the HER2/neu positive breast cancer targets. Unlike CD58 antibody-mediated ADCC, Herceptin ADCC was minimally affected by blocking antibodies to CD2 or ICAM-1/CD18, which suggests a different mechanism of action. This study shows that multiple mechanisms are involved in NK cell lysis of breast cancer targets, that none of the targets are inherently resistant to killing, and that two distinct mechanisms of ADCC can target immunotherapy to breast cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0301-472x(99)00089-2

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
Figure 1 IL-2-activated NK cells mediate significant cytotoxicity against breast cancer targets in vitro. (A) IL-2-activated populations of CD4 1 , CD8 1 , and NK cells were all generated from blood of normal donors and tested in cytotoxicity assays against the MCF-7 target. Activated NK cells (92 6 2% CD56 1 / CD3 2 ), but not CD4 1 or CD8 1 T cells, exhibited lysis of MCF-7 targets (n 5 3). (B) NK cells and autologous monocytes were obtained from normal donors and activated for 14 to 18 days with 1,000 U/mL IL-2. The resultant populations (90 6 3% CD56 1 /CD3 2 ) were tested in cytotoxicity assays against five breast cancer cell lines (MCF-7, T47D, MDA-MB-231, BT-20, SKBR-3).
Figure 1 IL-2-activated NK cells mediate significant cytotoxicity against breast cancer targets in vitro. (A) IL-2-activated populations of CD4 1 , CD8 1 , and NK cells were all generated from blood of normal donors and tested in cytotoxicity assays against the MCF-7 target. Activated NK cells (92 6 2% CD56 1 / CD3 2 ), but not CD4 1 or CD8 1 T cells, exhibited lysis of MCF-7 targets (n 5 3). (B) NK cells and autologous monocytes were obtained from normal donors and activated for 14 to 18 days with 1,000 U/mL IL-2. The resultant populations (90 6 3% CD56 1 /CD3 2 ) were tested in cytotoxicity assays against five breast cancer cell lines (MCF-7, T47D, MDA-MB-231, BT-20, SKBR-3).CC-BY · From the PDF
Figure 2 ICAM-1/CD18 interactions are involved in IL-2-activated NK lysis of breast cancer targets. IL-2-activated NK cells (96 6 2% CD56 1 / CD3 2 ) from normal donors were tested in cytotoxicity assays against breast cancer targets at an effector to target ratio of 4:1. Specific lysis was calculated for each target in the absence of antibody for T47D (79 6 3.4%), MDA-MB-231 (70 6 2.7%), BT-20 (45 6 9.3%), and SKBR-3 (53 6 9%). Data are presented as the percent of control with each antibody or combination as follows: [(% lysis with antibody 2 % lysis without antibody)/(% lysis without antibody)]. Each bar represents mean 6 SEM of 4 to 6 individual experiments analyzed in duplicate. There was significant inhibition of specific lysis for each breast cancer target involving recognition through b 2 integrins on NK cells. * p , 0.05.
Figure 2 ICAM-1/CD18 interactions are involved in IL-2-activated NK lysis of breast cancer targets. IL-2-activated NK cells (96 6 2% CD56 1 / CD3 2 ) from normal donors were tested in cytotoxicity assays against breast cancer targets at an effector to target ratio of 4:1. Specific lysis was calculated for each target in the absence of antibody for T47D (79 6 3.4%), MDA-MB-231 (70 6 2.7%), BT-20 (45 6 9.3%), and SKBR-3 (53 6 9%). Data are presented as the percent of control with each antibody or combination as follows: [(% lysis with antibody 2 % lysis without antibody)/(% lysis without antibody)]. Each bar represents mean 6 SEM of 4 to 6 individual experiments analyzed in duplicate. There was significant inhibition of specific lysis for each breast cancer target involving recognition through b 2 integrins on NK cells. * p , 0.05.CC-BY · From the PDF
Figure 3 Incubation of breast cancer targets with CD58 (AICD58) antibody enhances antibody-dependent cellular cytotoxicity. Resting NK cells were purified from normal donors by flow cytometry ( . 97% CD56 1 / CD3 2 ) and incubated with breast cancer targets at an effector to target ratio of 10:1 without activation with IL-2. Cytotoxicity was performed without (n 5 6) or with the addition of mouse IgG (n 5 6), anti-CD58 (clone AICD58, IgG2a, n 5 6), or anti-CD58 (clone BRIC-5, IgG2a, n 5 2). Each bar represents the percent specific lysis (mean 6 SEM) of experiments analyzed in duplicate. The CD58 (AICD58) antibody significantly enhanced lysis of all breast cancer targets as indicated compared to the mouse IgG control. No other differences were found.
Figure 3 Incubation of breast cancer targets with CD58 (AICD58) antibody enhances antibody-dependent cellular cytotoxicity. Resting NK cells were purified from normal donors by flow cytometry ( . 97% CD56 1 / CD3 2 ) and incubated with breast cancer targets at an effector to target ratio of 10:1 without activation with IL-2. Cytotoxicity was performed without (n 5 6) or with the addition of mouse IgG (n 5 6), anti-CD58 (clone AICD58, IgG2a, n 5 6), or anti-CD58 (clone BRIC-5, IgG2a, n 5 2). Each bar represents the percent specific lysis (mean 6 SEM) of experiments analyzed in duplicate. The CD58 (AICD58) antibody significantly enhanced lysis of all breast cancer targets as indicated compared to the mouse IgG control. No other differences were found.CC-BY · From the PDF
Figure 4 CD58-mediated antibody-dependent cellular cytotoxicity (ADCC) increases lytic activity in mononuclear cells (MNC) from patients receiving subcutaneous (SC) IL-2 but not in NK cells, which are CD16 negative. Peripheral blood mononuclear cells were obtained from patients treated for 14 to 28 days with SC IL-2 (1.75 3 10 6 U/m 2 /day) on a protocol to prevent relapse after autologous stem cell transplantation. Patient mononuclear cells (63 6 8% CD56 1 /CD3 2 , of which 87 6 2% expressed FcR g III [CD16]), without further IL-2 activation, were tested against the BT-20 breast cancer target at an effector to target ratio of 20:1. Cytotoxicity was significantly enhanced ( p , 0.05, n 5 4 patient samples performed in duplicate) when targets were pretreated with CD58 (AICD58) antibody compared to no antibody or IgG control. The requirement for FcR g III (CD16) on NK cells was tested further by generating NK cells from marrow CD34 1 progenitors in a long-term NK cell differentiation culture. IL-2 cultured NK cell progeny (97 6 1% CD56 1 /CD3 2 , of which 1.1 6 0.2% expressed FcR g III [CD16]) were tested against BT-20 at an effector to target ratio of 10:1. Unlike normal donor or patient-derived NK cells, the CD16 2 NK cells derived from marrow progenitors were unable to mediate ADCC when targets were pretreated with the CD58 (AICD58) antibody (n 5 4).
Figure 4 CD58-mediated antibody-dependent cellular cytotoxicity (ADCC) increases lytic activity in mononuclear cells (MNC) from patients receiving subcutaneous (SC) IL-2 but not in NK cells, which are CD16 negative. Peripheral blood mononuclear cells were obtained from patients treated for 14 to 28 days with SC IL-2 (1.75 3 10 6 U/m 2 /day) on a protocol to prevent relapse after autologous stem cell transplantation. Patient mononuclear cells (63 6 8% CD56 1 /CD3 2 , of which 87 6 2% expressed FcR g III [CD16]), without further IL-2 activation, were tested against the BT-20 breast cancer target at an effector to target ratio of 20:1. Cytotoxicity was significantly enhanced ( p , 0.05, n 5 4 patient samples performed in duplicate) when targets were pretreated with CD58 (AICD58) antibody compared to no antibody or IgG control. The requirement for FcR g III (CD16) on NK cells was tested further by generating NK cells from marrow CD34 1 progenitors in a long-term NK cell differentiation culture. IL-2 cultured NK cell progeny (97 6 1% CD56 1 /CD3 2 , of which 1.1 6 0.2% expressed FcR g III [CD16]) were tested against BT-20 at an effector to target ratio of 10:1. Unlike normal donor or patient-derived NK cells, the CD16 2 NK cells derived from marrow progenitors were unable to mediate ADCC when targets were pretreated with the CD58 (AICD58) antibody (n 5 4).CC-BY · From the PDF
Figure 5 Incubation of breast cancer targets with Herceptin (humanized anti-HER2/neu) mediates antibody-dependent cellular cytotoxicity. Resting NK cells were purified from normal donors and incubated with breast cancer targets at an effector to target ratio of 10:1 without activation with IL-2. Cytotoxicity was performed without antibody or with the addition of human IgG or Herceptin at 10 m g/mL (n 5 4 in triplicate). The Herceptin antibody significantly enhanced lysis of all breast cancer targets except MDA-MB-231, as indicated. Cytotoxicity with Herceptin is compared to the human IgG control.
Figure 5 Incubation of breast cancer targets with Herceptin (humanized anti-HER2/neu) mediates antibody-dependent cellular cytotoxicity. Resting NK cells were purified from normal donors and incubated with breast cancer targets at an effector to target ratio of 10:1 without activation with IL-2. Cytotoxicity was performed without antibody or with the addition of human IgG or Herceptin at 10 m g/mL (n 5 4 in triplicate). The Herceptin antibody significantly enhanced lysis of all breast cancer targets except MDA-MB-231, as indicated. Cytotoxicity with Herceptin is compared to the human IgG control.CC-BY · From the PDF
Image 7
CC-BY · From the PDF
Figure 7 CD58-mediated antibody-dependent cellular cytotoxicity (ADCC) but not Herceptin-mediated ADCC is dependent on CD2. (A) CD56 1 /CD2 2 NK cells were sorted by flow cytometry. An example of a representative sort with the collection window designated R2 is shown. (B) CD56 1 /CD2 2 NK cells, which are predominantly CD16 positive, were tested in cytotoxicity assays using the breast cancer target and antibodies as indicated. The CD2- NK cells exhibited CD16-dependent killing of Herceptin-treated SKBR-3 targets but had no effect on CD58 (AICD58) antibody-treated BT-20 targets.
Figure 7 CD58-mediated antibody-dependent cellular cytotoxicity (ADCC) but not Herceptin-mediated ADCC is dependent on CD2. (A) CD56 1 /CD2 2 NK cells were sorted by flow cytometry. An example of a representative sort with the collection window designated R2 is shown. (B) CD56 1 /CD2 2 NK cells, which are predominantly CD16 positive, were tested in cytotoxicity assays using the breast cancer target and antibodies as indicated. The CD2- NK cells exhibited CD16-dependent killing of Herceptin-treated SKBR-3 targets but had no effect on CD58 (AICD58) antibody-treated BT-20 targets.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 3

  1. Or, 1998, Allogenic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation, Cytokines Cell Mol Ther, 4, 1
  2. Leibson, 1995, Viewpoint, Nat Immun, 14, 117
  3. Lichtenstein, 1990, Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells, Cancer Res, 50, 7364

Cited by

See all 219

Metadata

Authors
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S.
Affiliations
University of Minnesota (US)
Corresponding author
Miller, Jeffrey S
Venue
Experimental Hematology
Publisher
Elsevier BV
Published
1999-10
Volume
27
Issue
10
Pages
1533-1541
ISSN
0301-472X (ISSN-L)
OpenAlex
W2039609199
Cited by
213
References
36
Citations by year
2025: 7 · 2024: 1 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 12 · 2019: 7 · 2018: 10 · 2017: 1 · 2016: 11 · 2015: 6 · 2014: 10 · 2013: 13 · 2012: 12
FWCI
1.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental Hematology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • American Cancer Society
  • American Society of Hematology
  • University of Minnesota
  • National Institutes of Health
  • National Cancer Institute (P01 CA65493, P01CA065493)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
natural killer cells, antibody-dependent cellular cytotoxicity, breast cancer, CD58, LFA-3, HER2/neu, trastuzumab, ICAM-1, CD18, CD2, Fc gamma receptor III, interleukin-2, adhesion molecules, immunotherapy
MeSH terms
Trastuzumab, Antibodies, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Breast Neoplasms, Cells, Cultured, Cytotoxicity Tests, Immunologic, Female, Flow Cytometry, Humans, Interleukin-2, Killer Cells, Natural, Lymphocyte Activation, Antigens, CD, Intercellular Adhesion Molecule-1, CD18 Antigens, CD58 Antigens, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. https://app.cochat.ai/papers/10.1016/s0301-472x(99)00089-2
The paper
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999). Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Experimental Hematology. https://doi.org/10.1016/s0301-472x(99)00089-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.